Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression
Molecular Psychiatry February 18, 2026 Marie Huc, Sara Siddiqi, Mysa Myers et al. 1 citation
Esketamine has emerged as a fast-acting antidepressant option for individuals with treatment-resistant depression (TRD). Yet, little is known about how sex-assigned-at-birth shapes symptom-specific responses to these interventions, a critical gap in the move toward precision psychiatry. To address this gap, we conducted a pooled analysis of five randomized, double-blind, placebo-controlled...